COST Earnings Preview: Margin Headwinds Test 54x P/E

The Core Question

Costco trades at ~54x trailing P/E — 39% above its 10-year average. The ensemble identifies a 55% probability of structural healthcare cost headwinds and a 50% probability of continued SG&A deleverage. Tomorrow's Q2 results will test both assumptions simultaneously.

For the complete seven-lens analysis covering moat durability, regulatory exposure, and unit economics, read the deep dive here.

Ensemble Forecast

Key Market

SG&A Deleverage 4+ Quarters

Probability

50%

Model Agreement

0.94

Strong consensus at maximum uncertainty

Our nine-model prediction ensemble is precisely split — 50% probability — on whether Costco's SG&A deleverage extends to 4+ consecutive quarters despite comp sales above 5%. This is the maximum-uncertainty point, and Q2 results will break the tie. Paired with the 55% probability of persistent healthcare cost headwinds, the ensemble identifies margin pressure as the central near-term risk to a 54x multiple. See all eight active markets on the COST forecasting page.

Earnings Scorecard — March 5

Comparable Sales Growth

Bull: >7%Bear: <5%

Revenue growth must sustain 8%+ to justify the premium multiple. Consensus expects ~$69.3B revenue (+8.8% YoY). Below 5% comps would challenge the “compounder” narrative at 54x P/E.

Gross Margin

Bull: >12.8%Bear: <12.5%

Currently 12.85% with only 35bps of buffer above the 12.5% escalation threshold. Section 122 tariffs at 10-15% pressure one-third of US sales (~$63B imported). Ensemble assigns 17% probability of breaching 12.5% by FY2026 end.

SG&A Leverage

Bull: Leverage achievedBear: 4th quarter deleverage

Three consecutive quarters of SG&A deleverage despite strong comps. The committee debated whether this reflects structural limits or deliberate investment. A fourth consecutive miss would tilt interpretation toward structural — pressuring OPERATIONAL_EXECUTION from EXCEEDING to MEETING.

Healthcare Cost Commentary

Bull: ModeratingBear: Structural

Emerged in Q1 FY2026 as healthcare costs exceeded sales growth. Management characterized it as structural. The ensemble assigns 55% probability it persists 3+ quarters — the most thesis-informative market, directly challenging the margin expansion narrative at 54x.

Membership Renewal Rate (US/CA)

Bull: >92%Bear: <91.5%

The foundational metric — 81.4M paid members at 92.2% US/CA renewal underpins the moat thesis. The ~20bps/quarter decline trend is unexplained. Ensemble assigns only 6% probability of falling below 88%, but any acceleration in the decline would warrant re-evaluation.

Current Assessment

Costco is classified as “Price Above Value” at medium confidence. The operational quality is genuine — 92.2% renewal, ~35.6% ROIC, $8.5B net cash, 3-year margin expansion. But at 54x P/E, the stock prices simultaneous revenue growth of 8%+, margin expansion, and sustained “compounder” classification. The ensemble identifies at least one of these pillars as facing headwinds. Read the full thesis assessment. We will update within 24 hours of the March 5 earnings release.

Full seven-lens analysis covering moat durability, regulatory exposure, unit economics, and all eight active prediction markets

COST Full Analysis COST Forecasts